Chapters

Transcript

Video

What did we learn specifically about the population of patients with post-ACS and T2D who were treated with alirocumab in the ODYSSEY Outcomes Trial?

What did we learn specifically about the population of patients with post-ACS and T2D who were treated with alirocumab in the ODYSSEY Outcomes Trial?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Vincent Woo, MD, FRCPC

Vincent Woo, MD, FRCPC

Endocrinology and Metabolism

Endocrinology and Metabolism
University of Manitoba
Principal Investigator
Diabetes Research Group
John Buhler Research Centre
Winnipeg, Manitoba, Canada